EClinCloud Expands Collaboration with Kangzhe Biotech to Help Improve Clinical Trial Efficiency with an Integrated Cloud Platform

Recently, EClinCloud signed a strategic cooperation agreement with Shenzhen Kangzhe Biotechnology Co., Ltd. (hereinafter referred to as "Kangzhe Biotech"). The two parties further expanded their collaboration, confirming that Kangzhe Biotech will adopt EClinCloud's EDC and RTSM systems.
Previously, Kangzhe Biotech had long used EClinCloud's eTMF system, eCOA system, and scale management services in clinical studies, and this collaboration marks deeper integration between the two parties in the field of clinical trials.
EClinCloud EDC goes beyond traditional EDC systems and better aligns with future trends; combining the strengths of multiple international EDC systems with the usage habits of users in China, it will help Kangzhe Biotech achieve digital and intelligent clinical trial data capture, remote data review, and transparent data standards.
The EClinCloud
RTSM system represents an
advanced, web-based randomization and drug supply management platform for multi-center clinical trials. Used to efficiently manage large-scale, multi-center clinical trials with multiple parallel protocol versions, it can help investigators control trial workflows more precisely, ensure smooth trial conduct, and improve the standardization of drug management.
Notably, as the scope of collaboration expands, the
"integrated" advantage across systems becomes even more pronounced, which will greatly help Kangzhe Bio improve data management efficiency and shorten R&D cycles. EClinCloud's integrated, interconnected platform brings together previously standalone systems, reducing duplicate data entry and cumbersome document management, while enabling data interoperability across systems to maximize the value of data.
Yin Yuanyuan, Head of Clinical Development / Head of Medical at China Medical System (CMS) Group, said:
"Expanding our collaboration with EClinCloud has greatly strengthened our confidence in optimizing clinical process management and improving data quality. Kangzhe Bio places great importance on informatization, digitalization, and intelligent technologies in clinical research. With EClinCloud's professional support, we believe we can greatly improve clinical operations efficiency, accelerate the drug launch process, and benefit patients broadly."
Dr. Qin Long, Founder and CEO of EClinCloud, said:
"Leveraging EClinCloud's interconnected, integrated cloud platform, we will provide Kangzhe Bio with more reliable digital solutions and further improve clinical data quality and overall project quality, using efficient, high-quality clinical operations to drive more R&D breakthroughs and benefit more patients."
About EClinCloud
With
"bringing effective treatments to patients through technological innovation" as its mission, it is a technology company focused on clinical research and development, providing an integrated, interconnected, unified clinical trial cloud platform and clinical trial endpoint assessment technologies across different therapeutic areas, combining cutting-edge technology with life data to build a globally leading "patient-centric" clinical evidence support SaaS cloud platform to help domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs/devices, and benefit countless patients
About Kangzhe Biopharma & China Medical System (CMS)
CMS Biopharma is a subsidiary of China Medical System
(867.HK). China Medical System is an open, platform-based enterprise linking pharmaceutical innovation and commercialization while managing the full product lifecycle. It focuses on first-in-class (FIC) and best-in-class (BIC) innovative products, efficiently advancing their clinical research, development, and commercialization, and enabling the continuous translation of scientific research achievements into clinical practice to benefit patients. Focusing on specialty areas, China Medical System has proven commercialization capabilities, broad channel coverage, and expert resources across multiple disease areas, with its core marketed products having achieved leading academic and market positions. China Medical System continues to deepen its development around its advantageous specialty areas to consolidate the competitiveness of its cardiovascular/cerebrovascular and gastroenterology businesses, while operating its dermatology and medical aesthetics as well as ophthalmology businesses independently to cultivate major leaders in niche specialty segments and improve specialty scale efficiency.


